Coronavirus disease 2019 in patients with neuroendocrine neoplasms: Preliminary results of the INTENSIVE study.
COVID-19
Coronavirus
Neuroendocrine neoplasms
Neuroendocrine tumours
SARS-CoV-2
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
received:
06
06
2021
accepted:
16
06
2021
pubmed:
24
7
2021
medline:
19
8
2021
entrez:
23
7
2021
Statut:
ppublish
Résumé
Specific data regarding coronavirus disease 2019 (COVID-19) in patients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive. This is a worldwide study collecting cases of patients with NENs along with a positive nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centres treating patients with NENs were directly contacted by the principal investigator. Patients with NENs of any primary site, grade and stage were included, excluding small-cell lung carcinoma and mixed adenoneuroendocrine carcinoma. Among 81 centres directly contacted, 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31 Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In most cases, they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.
Sections du résumé
BACKGROUND
Specific data regarding coronavirus disease 2019 (COVID-19) in patients with neuroendocrine neoplasms (NENs) are lacking. The aim of this study is to describe the characteristics of patients with NENs who tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive.
MATERIAL AND METHODS
This is a worldwide study collecting cases of patients with NENs along with a positive nasopharyngeal swab reverse transcriptase-polymerase chain reaction (RT-PCR) test for SARS-CoV-2 between June 1, 2020, and March 31, 2021. Centres treating patients with NENs were directly contacted by the principal investigator. Patients with NENs of any primary site, grade and stage were included, excluding small-cell lung carcinoma and mixed adenoneuroendocrine carcinoma.
RESULTS
Among 81 centres directly contacted, 88.8% responded and 48.6% of them declined due to lack of cases or interest. On March 31
CONCLUSIONS
Patients included in this study reflect the typical NEN population regardless of SARS-CoV-2. In most cases, they overcome COVID-19 without need of intensive care, short-term sequelae and discontinuation of systemic oncological therapy.
Identifiants
pubmed: 34298375
pii: S0959-8049(21)00404-4
doi: 10.1016/j.ejca.2021.06.029
pmc: PMC8241688
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
246-252Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article.
Références
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
Eur J Cancer. 2020 Nov;139:43-50
pubmed: 32971510
JNCI Cancer Spectr. 2021 Feb 24;5(2):pkaa102
pubmed: 33875976
Oncologist. 2020 Jul;25(7):548-551
pubmed: 32369669
Lancet Oncol. 2020 Oct;21(10):1309-1316
pubmed: 32853557
J Endocrinol Invest. 2021 May;44(5):989-994
pubmed: 32803662
J Clin Oncol. 2020 Oct 20;38(30):3538-3546
pubmed: 32795225
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Eur J Cancer. 2020 Dec;141:171-184
pubmed: 33161241
Indian J Palliat Care. 2020 Jun;26(Suppl 1):S173-S175
pubmed: 33088115
Eur J Cancer. 2020 Dec;141:92-104
pubmed: 33130550
Eur J Cancer. 2021 Feb;144:200-214
pubmed: 33370645
Int J Surg Case Rep. 2021 Mar;80:105703
pubmed: 33649715
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
JAMA Oncol. 2021 Feb 1;7(2):304-306
pubmed: 33331862
JAMA. 2021 Apr 2;:
pubmed: 33797550
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Eur J Cancer. 2020 Dec;141:62-81
pubmed: 33129039
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Surg Oncol. 2020 Sep;34:182-185
pubmed: 32891326
Pancreas. 2020 Jul;49(6):723-728
pubmed: 32433264
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
J Nucl Med. 2020 Aug;61(8):1094-1095
pubmed: 32576637
Endocrine. 2021 May;72(2):340-348
pubmed: 33786714
Endocrine. 2021 Jan;71(1):14-19
pubmed: 33400173
Cancer. 2021 Jan 15;127(2):266-274
pubmed: 33112411
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Ecancermedicalscience. 2020 May 22;14:1048
pubmed: 32565901
Cancer Discov. 2020 Jul;10(7):935-941
pubmed: 32357994
J Clin Med. 2020 Nov 11;9(11):
pubmed: 33187393
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2223-2226
pubmed: 32564170
Hell J Nucl Med. 2020 May-Aug;23 Suppl:31-34
pubmed: 32860394
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
J Natl Cancer Inst. 2021 Apr 6;113(4):371-380
pubmed: 33136163
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Eur J Endocrinol. 2020 Aug;183(2):G79-G88
pubmed: 32554825
Endocrine. 2020 Oct;70(1):6-10
pubmed: 32681385